Stockreport

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

Oculis Holding AG - Ordinary shares  (OCS) 
PDF ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused [Read more]